Stephanie V. Blank

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff et al. · Journal of Clinical Oncology · 2012 · 1.4K citations · Full text

Medicine, Gynecology, Oncology +16

Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer

Timothy R. Rebbeck, Nandita Mitra, Fei Wan et al. · JAMA · 2015 · 509 citations · Full text

Medicine, Genetics, Oncology +17

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

Fergus J. Couch, Xianshu Wang, Lesley McGuffog et al. · PLoS Genetics · 2013 · 391 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

Antonis C. Antoniou, Xianshu Wang, Zachary S. Fredericksen et al. · Nature Genetics · 2010 · 342 citations · Full text

Medicine, Genetics, Oncology +17

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12